Search
Mirum Pharmaceuticals Inc
MIRMAdd to Watchlist
93.180USD
-0.540-0.58%
Close 11-09 16:00（ET）
6.05BMarket Cap
LossP/E TTM
Mirum Pharmaceuticals Inc (MIRM) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Mirum Pharmaceuticals Inc in the past month.
Buy
6 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
155.849USD+83.35%
MIRM Analyst Recommendation Trends
In the current month, MIRM has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the last month is 155.849.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
6
6
6
6
5
4
4
4
8
8
8
8
8
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
14
14
13
11
11
11
MIRM Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, MIRM EPS is projected to reach -0.599 in FY2026Q4, following reported EPS of -0.622 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.35
-0.68
-0.49
-0.60
-0.33
Actual
-13.43
-1.06
-0.62
--
--
Surprise
-3699.95%
-55.81%
-27.46%
--
--
FAQs
What is Mirum Pharmaceuticals Inc's expected revenue for the next quarter?
Mirum Pharmaceuticals Inc's expected revenue is 191.91M.
What is Mirum Pharmaceuticals Inc's price target?
Analysts forecast that Mirum Pharmaceuticals Inc's price target is USD 157.42, with the highest forecast at USD 202.00 and the lowest forecast at USD 126.00.
How have Mirum Pharmaceuticals IncMIRM's recent earnings per share performed?
The market expectation was USD -0.62, while Mirum Pharmaceuticals IncMIRM's earnings per share (EPS) for the previous quarter was USD -1.06. EPS for the next quarter is expected at USD -0.60.
What is the analyst rating for Mirum Pharmaceuticals Inc?
Based on the ratings of Mirum Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.